This is the fourth in a series of articles designed to provide SXSW and LSI USA ’26 attendees and other MedTech professionals with practical considerations for efficiently executing mission-critical life science deals.

Many MedTech companies begin with one important relationship.

A health system agrees to test the product.
A strategic customer agrees to move first.
A commercial partner helps validate the market.

That is often how the first traction happens.

Founders do not always see how quickly that early relationship becomes part of how the company operates.

Most of these early deals start small. Over time, revenue starts depending on them. Product planning starts following them. And the business starts assuming the relationship will stay in place.

That is usually when financing questions begin.

By the time outside capital is being raised, the agreement may no longer feel like an early commercial arrangement. It may already function as part of how the company operates.

When an Early Deal Starts Driving the Business

Most early collaboration agreements are written for a limited purpose.

A defined deployment. Limited users. A narrow business objective.

What often happens is that the relationship continues without a full reset. One amendment becomes another. Pricing stays in place longer than expected. Operational expectations expand, but the original agreement still controls the relationship.

By the time diligence starts, the company may be relying on terms negotiated before anyone expected the relationship to matter this much.

Investors usually ask:

• How much of current revenue depends on this one agreement?
• Can the company expand without revisiting the existing terms?
• Does the other side have rights that affect future commercial decisions?
• If the relationship changes, how difficult is it to replace it?

An agreement that became central over time usually deserves a fresh review before financing begins.

Where Diligence Starts Focusing

Once one relationship drives a meaningful part of the business, contract terms that once felt manageable are read very differently in diligence.

Assignment provisions are one example.

A clause requiring consent before transfer may not seem important early. It matters once a financing structure, sale process, or internal reorganization is being evaluated.

The same is true for provisions that require notice, approval, or renegotiation if ownership changes.

These provisions do not always stop a transaction.

They often affect timing and negotiating leverage, which becomes important quickly once a deal is active.

Commercial Terms Often Get Revisited Late

Early-stage companies usually negotiate economics around what works at the time.

That is understandable. The immediate goal is getting the relationship in place.

Discounted pricing, preferred economics, milestone adjustments, or revenue-sharing terms may all feel workable when volumes are small.

The question is how those same terms look later.

A buyer usually asks whether margins still hold if revenue grows. Investors ask whether pricing flexibility remains if the company signs larger customers.

If a core agreement fixes economics too tightly, that often becomes a diligence issue even if the relationship itself is performing well.

Exclusivity Usually Becomes a Financing Question Later

Exclusivity often matters more once growth begins.

The issue usually comes up when a second strategic conversation starts, and the original agreement reads more broadly than anyone remembers.

What looked narrow early on can affect expansion into adjacent products, customer categories, or future enterprise relationships.

At that point, the practical question is simple.

Can the company move forward without reopening the first deal?

If the answer is uncertain, investors focus on it.

The Other Side Has More Leverage Once a Deal Starts

A strong commercial relationship can become a source of leverage once financing or sale discussions begin.

That is especially true if the company depends heavily on the relationship for revenue, validation, or market credibility.

At that point, even ordinary provisions carry more weight.

The other side may have consent rights. It may hold pricing protections. It may have the ability to reopen economics or delay approvals.

None of that may have mattered much when the agreement was signed, but it matters differently when transaction timing becomes important.

Preserving Flexibility Without Undermining the Relationship

The goal is not to negotiate every early agreement as if a sale is around the corner.

The goal is to avoid terms that become hard to manage once the company grows.

That usually means paying attention to:

• Assignment provisions that are too rigid.
• Pricing protections that last too long.
• Consent rights tied to ordinary growth decisions.
• Exclusivity that extends beyond the original business purpose.
• Provisions that reopen economics when ownership changes.

A strong early relationship should help the business grow. It should not quietly limit financing options later.

What Experienced Teams Do Differently

Teams that manage this well usually review important agreements before financing starts.

They look at what still fits and what no longer does.

They clean up terms where they can before diligence begins.

They understand that once outside capital arrives, old agreements are read differently.

Most early agreements are signed with good intent.

The question later is whether they still work when capital comes in or when a buyer starts evaluating risk.

By that point, the documents are no longer background. They are part of the deal.